UCB Just Paid $2.2 Billion for an Autoimmune Platform. The Indication List Tells You More Than the Deal Price.

UCB’s acquisition of Candid Therapeutics is being framed as a next-generation immunology platform deal. But beneath the immune-reset narrative lies a commercial reality few investors are discussing.